59 results
SC 14D9/A
PNT
POINT Biopharma Global Inc.
15 Nov 23
Tender offer solicitation (amended)
7:00am
the subsection titled “Regulatory Approvals” within the section titled “U.S. Nuclear Regulatory Commission” on page 43 as follows:
“POINT Biopharma USA Inc … approval from a nuclear regulator before they can be transferred, either directly or indirectly (e.g., through an upstream ownership change). On October 3
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
15 Nov 23
Third party tender offer statement (amended)
6:51am
INDIANAPOLIS, Nov. 14, 2023 – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission (“NRC”) has issued its
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
material respects of its obligations under the Merger Agreement; (v) consent by the
U.S. Nuclear Regulatory Commission (“NRC”) to the indirect … , POINT’s outside legal advisor specializing in nuclear law, had a meeting by teleconference to discuss the process for obtaining consent from
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
.
On September 15, 2023, representatives of Skadden, Kirkland & Ellis and Balch & Bingham LLP, POINT’s outside legal advisor specializing in nuclear law … , had a meeting by teleconference to discuss the process for obtaining consent from the Nuclear Regulatory Commission to transfer POINT’s materials
SC14D9C
EX-99.2
w8q01s1h
3 Oct 23
Written communication relating to third party tender offer
5:24pm
SC TO-C
EX-99.1
f6u5et
3 Oct 23
Information about tender offer
4:30pm
SC14D9C
EX-99.4
ayj 6b8tbo1avh
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
5zkj4fb5zi672ggwq5
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-2.1
t9qf8s1s fuk51
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.4
w78yn8yydhl3kx0
3 Oct 23
Tender and Support Agreement
7:35am
8-K
3950vpjek9c5mwtf jw
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-2.1
tfzslmn hv786q
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
zvnf19r85m8jdw
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
klmpl91nmmndysvv
1 May 23
Annual report to shareholders
1:52pm
424B5
ds89met
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
mcn 1phztsb
13 Sep 22
Prospectus supplement for primary offering
5:19pm